(Q71843572)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8948272%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

title

Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8948272%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

author name string

J R Tucci

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8948272%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

R P Tonino

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8948272%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

R D Emkey

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8948272%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

C A Peverly

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8948272%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

U Kher

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8948272%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

A C Santora

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8948272%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

publication date

1 November 1996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8948272%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Medicine

21 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8948272%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

volume

101

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8948272%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8948272%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

page(s)

488-501

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8948272%20AND%20SRC:MED&resulttype=core&format=json

Involutional osteoporosis

21 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

Preclinical pharmacology of alendronate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

Etidronate disodium in postmenopausal osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

Effect of spinal osteophytosis on bone mineral density measurements in vertebral osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

Testing the statistical certainty of a response to increasing doses of a drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

Testing for qualitative interactions between treatment effects and patient subsets.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

Pamidronate: an unrecognized problem in gastrointestinal tolerability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

The coupling of bone formation to bone resorption: a critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

Epidemiology of osteoporosis and osteoporotic fractures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

Outcome variables in osteoporosis trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

Treatment of postmenopausal osteoporosis with transdermal estrogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

17 Beta-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

Design of the Fracture Intervention Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900282-3

10.1016/S0002-9343(96)00282-3

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8948272%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

1 reference